A Novel Liquid Biopsy Test
for Longitudinal Cancer Monitoring and Minimal Residual Disease Detection

Real-time results Swift and accurate reporting

Comprehensive reports CTC number, ctDNA%, and relevant mutations

Minimal residual disease detection Uncover residual cancer cells post-treatment

Longitudinal Monitoring Assess disease dynamics over time

What is OncoMonitor?

OncoMonitor is a blood test designed for longitudinal monitoring of cancer patients. The test includes measurements of:

  1. Circulating Tumor Cells (CTC) number

  2. Circulating Tumor DNA (ctDNA) load

  3. Pertinent mutations to aid in monitoring disease progression and detecting minimal residual disease in cancer patients.

Key actionable genes included:

Test Benefits

Longitudinal Monitoring

By regularly assessing CTC numbers and ctDNA load, oncologists can gain insights into the dynamics of the disease, its response to treatment, and potential disease relapse.

Minimal Residual Disease Detection

OncoMonitor’s ability to identify trace amounts of CTCs and ctDNA allows for early detection of residual cancer cells post-treatment, enabling timely intervention and improved patient outcomes.

Treatment Efficacy Assessment

Changes in CTC counts and ctDNA levels can indicate whether the current treatment approach is successful or if modifications are necessary to enhance its impact.

Prognostic Value

CTC and ctDNA levels have shown prognostic significance in various cancers. The test results can help predict disease progression and overall survival, aiding in informed decision-making for both patients and healthcare providers.

Test Features

  • SNVs and indels: Covers clinically actionable or relevant genes covering over 1000 targets

  • Including amplifications of EGFR, ERBB2 (HER2), MET, MYC, FGFR2, KIT, CCND1, CD274 etc

  • Translocations (Fusions) of ALK, ROS1, FGFR1/2/3, NTRK1/2/3, RET etc

  • MSI status by NGS

  • PD-L1 through immunofluorescence on OncoDiscover-CTC

  • Mean sequencing depth: 5000X

  • TAT: 10–12 working days

  • Indications: Solid Tumors

  • Sample collection: Peripheral blood

  • On target coverage: >99%

  • CTC detection by DCGI–approved OncoDiscover® Technology

For which cancer phase is OncoMonitor most applicable

Clinical Scenarios

  • Guiding adjuvant therapy decision post-surgery eg Stage II colon cancer (DYNAMIC), stage IB-IIIA NSCLC (CONFIRM), early-stage breast cancer(TAILORx)

  • Evaluating the efficacy of neoadjuvant and adjuvant therapies in various cancers eg patients with resectable stage IB to IIIA in NSCLC (CheckMate 816), Stage II or III CRC (DETECT-A, COMPASS)

  • When a relapsed disease is likely to be very small (<1cm) and may be missed on PET-scan (early relapse)

  • Monitoring patients who are on long-term maintenance therapy e.g., oral anticancer-drugs